Welcome to our dedicated page for Baird Medical news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical stock.
About Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)
Baird Medical Investment Holdings Ltd. is a globally recognized innovator in minimally invasive microwave ablation (MWA) technology. Established in 2012 and headquartered in Guangzhou, China, the company develops and provides advanced medical devices designed for the treatment of both benign and malignant tumors. Baird Medical's proprietary MWA technology offers cutting-edge solutions for conditions such as thyroid nodules, liver cancer, lung nodules, breast lumps, and uterine fibroids. As a publicly traded company on the NASDAQ under the ticker symbol BDMD, Baird Medical is committed to enhancing patient care through innovative, precise, and efficient medical devices.
Core Technology: Microwave Ablation (MWA)
Microwave ablation is a minimally invasive treatment technique that uses microwave energy to generate extreme heat, denaturalizing and coagulating tumor cell proteins. Compared to traditional surgical methods, MWA offers a range of advantages, including shorter recovery times, lower complication rates, and ease of operation. Baird Medical has pioneered advancements in this field, with its devices being the first in China to receive a Class III medical device registration certificate specifically for thyroid nodules. The company’s technology is increasingly recognized as a safer and more efficient alternative to traditional treatments like thyroidectomy and radiofrequency ablation (RFA).
Global Expansion and Regulatory Milestones
Baird Medical has achieved significant milestones in its global expansion strategy. Following its 2024 listing on the NASDAQ, the company has successfully entered the U.S. market with FDA 510(k) clearances for its MWA devices. This regulatory approval has enabled Baird Medical to address a substantial unmet need in the U.S., where approximately 150,000 thyroidectomies are performed annually. The company’s devices are now being adopted by leading healthcare institutions, including Columbia University, Weill Cornell, and Tulane University.
Market Position and Competitive Edge
Operating in the specialized field of tumor ablation, Baird Medical differentiates itself through its focus on innovation, safety, and efficiency. Its MWA technology provides larger ablation zones and shorter treatment times compared to competing methods. The company also invests heavily in physician training and academic collaborations, fostering a strong network of key opinion leaders (KOLs) and healthcare providers globally. These initiatives not only enhance the adoption of its technology but also strengthen its reputation as a trusted partner in advancing minimally invasive medical solutions.
Commitment to Academic Collaboration and Training
Baird Medical actively participates in global academic and clinical forums, such as the American Thyroid Association (ATA) Annual Meeting and the American College of Surgeons (ACS) Clinical Congress. The company also organizes specialized training programs and conferences, such as the Global Thyroid Microwave Ablation Technology Exchange Conference, to educate physicians on the latest advancements in MWA technology. These efforts underline Baird Medical’s dedication to fostering innovation and improving clinical practices in tumor treatment.
Future Outlook
With a strong foundation in China and growing presence in international markets, Baird Medical is well-positioned to expand its influence in the field of minimally invasive tumor treatments. The company’s focus on research and development, coupled with strategic partnerships and regulatory achievements, ensures its continued growth and contribution to advancing global healthcare standards.
Key Advantages of Baird Medical
- Proprietary MWA technology offering safer and more efficient tumor treatments.
- Regulatory clearances, including FDA 510(k), enabling global market access.
- Strong academic and clinical collaborations to drive technology adoption.
- Commitment to physician training and education, enhancing clinical outcomes.
- Focus on minimally invasive solutions, reducing patient recovery times and healthcare costs.
Baird Medical Investment Holdings (NASDAQ: BDMD) hosted a delegation of Bangladeshi physicians at its Guangzhou headquarters for an expert-led microwave ablation (MWA) training program. The delegation included four doctors who participated in theoretical discussions and hands-on demonstrations at Baird's facility.
The training continued at Sun Yat-sen University Cancer Center, where participants observed live MWA procedures for liver and lung ablations, followed by discussions with specialists. The program concluded with a session on thyroid microwave ablation techniques led by Dr. Feng Han in the hospital's Ultrasound Department.
Chairwoman Haimei Wu emphasized the company's commitment to global knowledge-sharing and medical innovation through cross-border collaboration.
Baird Medical Investment Holdings (NASDAQ: BDMD) recently supported a specialized microwave ablation (MWA) training program at the Columbia Thyroid Center in New York City. The two-day course, led by Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program, provided comprehensive instruction on MWA techniques, safety, and clinical applications.
The training attracted physicians from the US and Mexico, including Dr. Hosai Todd-Hesham and Dr. Camilo González Velázquez. Participants engaged in hands-on training with thyroid models and observed three live procedures, including the successful ablation of a 5cm thyroid nodule. The program focused on device operation, ablation precision, and real-time procedural adjustments.
This initiative is part of Baird Medical's commitment to expanding its global MWA education network and accelerating the adoption of minimally invasive treatments through standardized training and collaboration.
Baird Medical (NASDAQ: BDMD) made a notable presence at the 2025 North American Society for Interventional Thyroidology (NASIT) conference, showcasing its advanced microwave ablation (MWA) technology for thyroid treatment. The company's exhibit generated significant interest, facilitating meaningful discussions with healthcare professionals about minimally invasive thyroid therapies.
A key highlight was a keynote presentation by Dr. Emad Kandil from Tulane University School of Medicine, who presented case studies and clinical data demonstrating MWA's advantages, including reduced procedure times, fewer complications, and improved patient outcomes. The presentation garnered substantial attention and sparked engaging discussions, underlining the industry's interest in MWA technology.
Through the conference, Baird Medical reinforced its position in advancing patient care through innovation and strengthened its collaborations with medical professionals in the field of minimally invasive thyroid treatments.
Baird Medical (NASDAQ: BDMD), a leader in microwave ablation technology, participated in the 2025 Microcap Conference at the Borgata Hotel in Atlantic City. The event, which attracted over 750 institutional investors and industry experts, served as a platform for the company to showcase its minimally invasive microwave ablation technology and discuss its recent FDA 510(k) clearance for the U.S. market.
During the conference, Baird Medical's leadership team conducted one-on-one meetings with investors to outline U.S. market penetration strategies and engaged in discussions about potential mergers and acquisitions. Chairwoman Haimei Wu emphasized the conference's role in connecting with global investors and identifying collaboration opportunities. The company plans to leverage these insights to advance its global expansion while continuing investments in research and development.
Baird Medical Investment Holdings (NASDAQ: BDMD) marked a transformative year in 2024, highlighted by its successful Nasdaq listing on October 2. The company, specializing in Microwave Ablation (MWA) technology, secured multiple patents enhancing MWA technology and production efficiency.
Key achievements include obtaining a Class III Medical Device Production License in China and receiving notable industry recognition, including designation as a Jiangsu Province High-Tech Enterprise. The company's subsidiary, Nanjing Great Wall, strengthened its position with four new patents focused on vascular thermal coagulation and RF ablation catheter optimization.
Nanjing Great Wall also secured a Class III Medical Device Registration Certificate in China for its Disposable Microwave Ablation Needle and obtained ISO 13485 certification, enhancing its international market access. These developments position Baird Medical for continued global expansion and advancement in minimally invasive treatment solutions.
Baird Medical Investment Holdings (NASDAQ: BDMD) has announced its participation in the 2025 North American Society for Interventional Thyroidology (NASIT) Conference, scheduled for January 31 – February 1, 2025, in Washington, D.C. The company, known for its leadership in Minimally Invasive Microwave Ablation (MWA) technology, will return to this premier thyroid interventions forum.
During the conference, Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, will present at the Product Theater, following his achievement of completing 100 MWA cases. The event provides Baird Medical with opportunities to engage with global experts, industry leaders, and potential partners while contributing to discussions on MWA technology advancements.
The company aims to gain insights into industry trends, optimize strategic initiatives, and continue driving innovation in global healthcare through this participation.
Baird Medical (NASDAQ: BDMD), a pioneer in microwave ablation technology (MWA), has announced its participation in the upcoming Microcap Conference at the Borgata Hotel, Atlantic City, from January 28-30, 2025. The company, which specializes in developing advanced needles and apparatus for thyroid nodule microwave ablation, offers a minimally invasive alternative to traditional open neck surgery.
Following their FDA 510(k) clearance in November 2023 and with an established market leadership in China, Baird Medical is strategically positioned for global expansion. Chairwoman Haimei Wu emphasized the significance of their FDA clearance and the opportunity to showcase their innovations at the conference.
The annual Microcap Conference will feature company presentations and one-on-one meetings with investors. Interested parties can schedule meetings by contacting maxm@bairdmed.com.
Baird Medical (NASDAQ: BDMD) announces expansion into San Francisco as part of its U.S. growth strategy, following its participation in the J.P. Morgan Health Conference. Dr. Terrence K. Trapp, an otolaryngologist, has integrated the company's Microwave Ablation (MWA) system into his practice.
Since receiving FDA 510(k) clearance in November 2023, the company has treated hundreds of U.S. patients with its MWA technology, reporting positive treatment outcomes. Notable adoption includes Dr. Emad Kandil at Tulane University, who has performed over 100 MWA procedures.
The company is focusing on expanding physician education and awareness of MWA technology through collaboration with medical specialists and comprehensive training support.
Baird Medical Investment Holdings (NASDAQ: BDMD) announced that Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, has completed 100 Microwave Ablation (MWA) procedures for thyroid nodules. This milestone demonstrates the increasing adoption of MWA technology in thyroid treatment.
Dr. Kandil's achievement highlights MWA as a safe and effective alternative to traditional thyroid surgery, offering benefits such as faster recovery times, reduced procedural risks, and improved quality of life. Baird Medical presented Dr. Kandil with a Certificate of Excellence for his contributions to advancing thyroid care.
The company reaffirmed its commitment to advancing MWA technology through continued collaboration with physicians and investment in medical education.
Baird Medical (NASDAQ: BDMD), a leader in minimally invasive Microwave Ablation (MWA) technology, participated in activities surrounding the 2025 J.P. Morgan Healthcare Conference in San Francisco. Following its Nasdaq debut in October 2024, the company engaged with healthcare investors and industry leaders, discussing advancements in microwave ablation technology and patient outcomes.
Chairwoman Haimei Wu highlighted the conference's importance in connecting with shareholders, innovators, and healthcare sector advisors. The company plans to utilize these interactions to support its 2025 strategic initiatives, focusing on expanding its U.S. presence and strengthening collaborations with key opinion leaders (KOLs) in medical technology.
FAQ
What is the current stock price of Baird Medical (BDMD)?
What is the market cap of Baird Medical (BDMD)?
What does Baird Medical specialize in?
How does microwave ablation technology work?
What are the advantages of Baird Medical's MWA devices?
Where is Baird Medical headquartered?
What regulatory approvals has Baird Medical achieved?
How does Baird Medical support physicians and healthcare providers?
What conditions can Baird Medical's devices treat?
What is the significance of Baird Medical's entry into the U.S. market?
How does Baird Medical differentiate itself from competitors?
What is Baird Medical's long-term vision?
